What memodio does

memodio GmbH is a Potsdam-based digital health company that develops and operates a prescription digital therapeutic (DiGA) for the prevention and therapy of mild cognitive impairment (MCI) and mild dementia. The product is a Class I medical device (Medizinprodukt Klasse I) under the EU Medical Device Regulation, delivered as a mobile application on iOS and Android. It received DiGA approval from the German Federal Institute for Drugs and Medical Devices (BfArM) in January 2026 (PZN 20386496), making it fully reimbursable by all German statutory health insurers. The therapeutic approach is built on the FINGER multi-domain intervention model and combines six components: adaptive cognitive training, physical exercise, nutritional guidance, risk factor optimization (e.g., hypertension, dyslipidemia, hearing loss), social participation, and health literacy. Exercises auto-adjust in difficulty based on user performance, and a motivational system (virtual plant growing with completed exercises) supports adherence. Clinical validation was conducted via the MEMODIO_APP@CARE randomized controlled trial (n=140), which demonstrated statistically significant improvements in cognitive function (MoCA +9.3%, p<0.001), daily functioning (Amsterdam iADL +5.5%, p=0.002), physical activity (PAQ 50+ +21%, p=0.036), and quality of life (DemQOL +4.4%, p=0.025) over 12 weeks.

memodio is distributed exclusively through the regulated German prescription channel. Patients obtain the app via a physician's prescription (Kassenrezept or private prescription) for the indications MCI (F06.7), mild dementia (F00/F01), or Senilität (R54); memodio coordinates with health insurers to issue a 16-digit activation code. Therapy cycles are 12 weeks per prescription with follow-up prescriptions possible. Revenue flows from per-prescription-cycle reimbursements by statutory and private health insurers, with the company reporting 10,000+ users as of 2025. The company maintains ISO/IEC 27001:2022 certification, GDPR-compliant data processing, and uses the FHIR standard (MIO DiGA Toolkit v1.1.0) for data portability. A Scientific Advisory Board of leading German and European dementia researchers, including Prof. Mangialasche from the FINGER Network at Karolinska Institutet, provides clinical and scientific oversight. memodio is also developing a Spanish-market version (memodio vida). The company was founded in 2021 by Dr. Doron B. Stein, Dr. Felix Bicu, and Paul Zimmermann.

Name

memodio

Legal name

memodio GmbH

Website

https://memodio-app.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

memodio GmbH operates a German DiGA-approved prescription digital therapeutic (mobile app) that delivers personalized, multi-domain cognitive, physical, nutritional, and risk-factor therapy to patients with mild cognitive impairment and mild dementia, reimbursed by statutory health insurers.

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Home Health Care Services (62161), Services for the Elderly and Persons with Disabilities (624120)

SIC

Services-Prepackaged Software (7372), Services-Health Services (8000), Services-Home Health Care Services (8082)

akta.pro primary industry

Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)

akta.pro secondary industry

Cognitive Stimulation & Reminiscence Therapy (Non-Clinical) (HSABAEAH)

Keywords

• Digital therapeutics
• Dementia prevention
• Cognitive training software
• Digital health applications
• Medical device software

Headquarters

HQ city

Potsdam

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. DiGA Prescription Reimbursement: memodio is listed as a DiGA (Digitale Gesundheitsanwendung) in Germany. It is prescribed by physicians (GPs, specialists, psychotherapists) via statutory health insurance (GKV). All costs are covered 100% by statutory health insurers for patients — no co-payment required. Private health insurers also reimburse memodio. Revenue flows from insurer reimbursements to the company per prescription cycle.
2. Seed Funding: memodio raised €400,000 in a seed financing round in February 2023, co-financed by private investors via Companisto (crowdfunding platform). Additional public funding was received from EXIST, the German Federal Ministry for Economic Affairs and Climate Action, and the European Union / State of Brandenburg.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

memodio develops and operates a DiGA (Digitale Gesundheitsanwendung — Digital Health Application) mobile app that delivers a personalized, multi-domain therapy program for adults with mild cognitive impairment (MCI) and mild dementia. The app combines adaptive cognitive training, guided physical exercise, brain-healthy nutrition guidance, social participation content, risk factor optimization, and health literacy into a single auto-adaptive daily therapy unit of approximately 20 minutes. It is prescribed by physicians in Germany on a Kassenrezept or private prescription and is fully reimbursed by statutory and private health insurers (PZN 20386496).

Product overview

memodio is a single, unified mobile application (DiGA — Digitale Gesundheitsanwendung) for dementia prevention and therapy. The core product is the memodio App, which integrates all non-pharmacological treatment components — cognitive brain training, physical exercise programs, dietary/nutrition guidance, risk factor optimization (e.g., blood pressure, hearing loss), social participation, and health literacy education — into one personalized, auto-adaptive daily therapy unit. The app is prescribed by physicians (PZN 20386496) and fully reimbursed by German statutory health insurers. A clinical study (MEMODIO_APP@CARE, n=140) demonstrated measurable improvements in cognitive function, daily living independence, physical activity, and quality of life after 12 weeks. memodio also provides a CME (continuing medical education) program for healthcare professionals.

Differentiator

Problem solved

Functional benefit

Products and services

• memodio App Mobile digital therapeutic (iOS 12+ and Android 6+) prescribed by physicians in Germany as a Class I medical device (DiGA, PZN 20386496) for adults with mild cognitive impairment (ICD-10 F06.7) or mild dementia (F00/F01). Delivers a personalized, auto-adaptive daily therapy unit of approximately 20 minutes combining cognitive training, physical exercise, brain-healthy nutrition guidance, social participation content, risk factor optimization (e.g., hypertension, dyslipidemia, hearing loss), and health literacy modules. Fully reimbursed by German statutory and private health insurers upon prescription, with therapy delivered as 12-week prescription cycles (follow-up prescriptions possible).

Quantifiable outcome

• 9.3% improvement in cognitive function (MoCA score) vs. control group after 12 weeks (p<0.001)
• +6 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature8 records

Partnerships

Six partnerships are on record, tiered minor and core.

• SpinLab – The HPI AcceleratorminorStrategic or Co-development PartnerSpinLab, the HPI accelerator, is listed as a partner supporting memodio's development and growth.
• Copenhagen Business School (CBS)minorStrategic or Co-development PartnerCopenhagen Business School (CBS) in Denmark is listed as a clinical and scientific partner supporting memodio's research.
• Potsdam Transfer / University of PotsdamminorStrategic or Co-development PartnerPotsdam Transfer and the University of Potsdam support memodio as an academic and technology transfer partner, including hosting the company at their facilities (c/o Potsdam Transfer).
• Medizinische Hochschule Theodor Fontane (MTH) PotsdamminorStrategic or Co-development PartnerMTH Potsdam is listed as a clinical and scientific partner supporting memodio's development.
• FINGER Network (Karolinska Institutet)coreStrategic or Co-development PartnerThe FINGER Network (FINGERS Brain健康) coordinated by the Karolinska Institutet in Stockholm is a core strategic partner. memodio's therapeutic approach is based on the FINGER model — a landmark multi-domain intervention trial demonstrating that combined physical, cognitive, nutritional, and vascular risk management can prevent cognitive decline. Prof. Mangialasche (FINGER Vice-President) serves on memodio's Scientific Advisory Board.
• memodio Scientific Advisory BoardcoreStrategic or Co-development PartnerThe Scientific Advisory Board includes Prof. M.C. Polidori (University Hospital Cologne), Prof. E. Kalbe (University Hospital Cologne), Prof. S. Schneider (German Sport University Cologne), Prof. M. Heer (Bonn University of Applied Sciences), Prof. G. Nelles (Deutsche Gesellschaft für Neurologie), Dr. A. Quante (Gedächtnisklinik Berlin), Prof. Mangialasche (FINGER Network, Karolinska), and Prof. P. Mecocci (Italian Academy of Geriatrics). The board provides clinical and scientific oversight to ensure the app meets the highest medical standards.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key risks3 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about memodio